Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology
09 janv. 2023 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Vaccinex Announces $3.8 Million Private Placement
28 nov. 2022 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET
25 mai 2022 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., May 25, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update
16 mai 2022 08h15 HE
|
Vaccinex, Inc.
Excellent Progress in Pepinemab Clinical Programs Promising responses in Phase 1b segment of the open-label KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck...
Vaccinex, Inc. Announces Upcoming Presentation at the PEGS Boston Conference & Expo Highlighting Its ActivMAb® Technology for Complex Membrane Antigen Expression to Enable Drug Discovery
25 avr. 2022 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., April 25, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and...
Vaccinex, Inc. Announces Research Collaboration Employing ActivMAb® Platform Technology and Antibody License Option Agreement with Surface Oncology
08 janv. 2018 13h10 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a privately-held clinical-stage biotechnology company engaged in the development of therapeutic monoclonal antibodies to treat...